Inhibrx Biosciences said the FDA has accepted its Biologics License Application for ozekibart in unresectable or metastatic conventional chondrosarcoma, marking a key regulatory milestone. The filing does not imply approval, but it advances the drug toward a potential commercial decision. The update is modestly positive for INBX and could support the stock on regulatory progress.
Inhibrx Biosciences said the FDA has accepted its Biologics License Application for ozekibart in unresectable or metastatic conventional chondrosarcoma, marking a key regulatory milestone. The filing does not imply approval, but it advances the drug toward a potential commercial decision. The update is modestly positive for INBX and could support the stock on regulatory progress.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.40
Ticker Sentiment
